Transplant Hepatology

Dr. Ramu Chimakurthi

Senior Consultant – Transplant Hepatology

20 Years of Experience

NKG: 9AM - 5PM

Qualifications

  • MBBS
  • MRCP (UK, London) – Gastroenterology & General Internal Medicine
  • Post CCT Fellowship in Hepatology, Leeds Liver Unit, UK

Experience

United Kingdom (NHS)

  • Consultant Transplant Hepatologist, Leeds Liver Unit, Leeds Teaching Hospitals NHS Trust
  • Post CCT Fellow in Hepatology, Leeds Liver Unit
  • Specialist Registrar – Gastroenterology, Hepatology & Internal Medicine
    Royal Devon & Exeter Hospital
    Plymouth Teaching Hospitals
    Torbay Hospitals
    North Devon District Hospital
  • Core Medical & Specialty Trainee, Torbay & Plymouth Hospitals
  • Foundation Training, Lewisham, Kent & Canterbury Hospitals

India

House Surgeon, Government General Hospital, Kakinada

Field of Expertise

  • Liver Transplantation (Pre- & Post-transplant Care)
  • Living Donor Liver Transplantation
  • Immune-Mediated Liver Diseases - AIH, PSC, PBC, Sarcoidosis
  • Viral Hepatitis (A–E, CMV)
  • Alcohol Related & Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
  • Decompensated Cirrhosis & Complications - Ascites, Variceal Bleeding, Hepatic Encephalopathy
  • Acute & Acute-on-Chronic Liver Failure
  • Pregnancy-Associated Liver Disease
  • Genetic Cholestatic Liver Disorders
  • Drug-Induced Liver Injury (DILI)
  • Portal Hypertension, Budd-Chiari Syndrome, TIPSS
  • Hepatocellular Carcinoma (HCC)

Research & Publications

  • Checkpoint Inhibitor Induced Cholangiopathy-  Frontline Gastroenterology Nov 2025.
  • O33 CM101, a novel monoclonal antibody targeting CCL24, in patients with primary sclerosing cholangitis: results from spring study -  Conference Paper BSG June 2025.
  • Global Variation in Living Donor Liver Transplantation Practices Impacts Donor and Recipient Short-Term Outcomes: Initial Insights from the International LDLT Registry. - American Journal of Transplantation Apr 25 (Contributed data).
  • Decompensated cirrhosis – a timely intervention?- Abstract/Conference Paper BASL 2024
  • Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study- JHEP Reports-2023.
  • NAFLD in Psoriatic Disease: Identifying patients at high risk of serious liver disease. -Annals of the Rheumatic Diseases. May 2023.
  • Non-Alcoholic Fatty liver disease in spondyloarthritis: Identifying patients on therapy at high risk of serious liver disease. -British Journal of Rheumatology. April 2023.
  • Endovascular glue embolization for parastomal variceal bleeding: A retrospective analysis of patient outcomes.- Gut Abstracts for BASL 2022.
  • Outcomes following Immune Checkpoint inhibitor re-challenge in patients who developed grade 3 and 4 hepatotoxicity. -Poster presentation-EASL ILC 2022 (EASL, Abstract Number 3419).
  • UK Wide Evaluation of Second Line Therapies in Primary Biliary Cholangitis.- Poster presentation-EASL ILC 2021.
  • Multicentre evaluation of second-line therapies in primary biliary cholangitis: UK experience.- Conference Paper, GUT-BSG 2021.
  • Experience of shielding during the first wave of COVID-19 amongst UK patients with autoimmune hepatitis (AIH) -Conference Paper, GUT-BSG 2021.
  • T Cell response in immunosuppressed redo-liver transplant recipients after COVID 10 infection and after the first dose of vaccine against SARS COv-2.-Conference Paper, ILTS 2021.
  • Non-directed altruistic living liver donation: Evaluation and outcomes.- HPB-2020.
  • Ambulatory liver services avoid admissions and reduce length of stay with high patient satisfaction.-Conference paper, GUT-BSG 2018.
  • The risk of chronic kidney disease after liver transplantation is rising in parallel with the increased use of higher-risk grafts. -Journal of Hepatology, Vol 66, Issue 1, S192. & -Poster presentation by one of the authors at EASL ILC 2017.
  • Management of High-Risk Colonic Polyps -An Audit of Current Practice.- Poster presentation in GUT-BSG 2014.
  • Botulinum Toxin Use in Oesophageal Dysmotility.- Poster presentation GUT-BSG 2014.
  • Prospective Study of Peristomal Infections After Percutaneous Endoscopic Gastrostomy Over A 4-year Period.-Poster presentation UEG 2014.
  • Endoscopy Comfort- Views and Practices of BCSP (Bowel Cancer Screening Programme) Colonoscopists in Southwest England. 2012. - Poster presentation in SWG Meeting 2012.
  • Oral presentation on Long QT Interval – A Case Study in Southwest -Electrophysiology Group in 2007.

Certifications & Memberships

 Memberships

  • British Association for the Study of the Liver (BASL)
  • European Association for the Study of the Liver (EASL)
  • Royal College of Physicians, London (RCP London)
Nanakramguda | Banjara Hills

Qualifications

  • MBBS
  • MRCP (UK, London) – Gastroenterology & General Internal Medicine
  • Post CCT Fellowship in Hepatology, Leeds Liver Unit, UK

Experience

United Kingdom (NHS)

  • Consultant Transplant Hepatologist, Leeds Liver Unit, Leeds Teaching Hospitals NHS Trust
  • Post CCT Fellow in Hepatology, Leeds Liver Unit
  • Specialist Registrar – Gastroenterology, Hepatology & Internal Medicine
    Royal Devon & Exeter Hospital
    Plymouth Teaching Hospitals
    Torbay Hospitals
    North Devon District Hospital
  • Core Medical & Specialty Trainee, Torbay & Plymouth Hospitals
  • Foundation Training, Lewisham, Kent & Canterbury Hospitals

India

House Surgeon, Government General Hospital, Kakinada

Field of Expertise

  • Liver Transplantation (Pre- & Post-transplant Care)
  • Living Donor Liver Transplantation
  • Immune-Mediated Liver Diseases - AIH, PSC, PBC, Sarcoidosis
  • Viral Hepatitis (A–E, CMV)
  • Alcohol Related & Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
  • Decompensated Cirrhosis & Complications - Ascites, Variceal Bleeding, Hepatic Encephalopathy
  • Acute & Acute-on-Chronic Liver Failure
  • Pregnancy-Associated Liver Disease
  • Genetic Cholestatic Liver Disorders
  • Drug-Induced Liver Injury (DILI)
  • Portal Hypertension, Budd-Chiari Syndrome, TIPSS
  • Hepatocellular Carcinoma (HCC)

Research & Publications

  • Checkpoint Inhibitor Induced Cholangiopathy-  Frontline Gastroenterology Nov 2025.
  • O33 CM101, a novel monoclonal antibody targeting CCL24, in patients with primary sclerosing cholangitis: results from spring study -  Conference Paper BSG June 2025.
  • Global Variation in Living Donor Liver Transplantation Practices Impacts Donor and Recipient Short-Term Outcomes: Initial Insights from the International LDLT Registry. - American Journal of Transplantation Apr 25 (Contributed data).
  • Decompensated cirrhosis – a timely intervention?- Abstract/Conference Paper BASL 2024
  • Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study- JHEP Reports-2023.
  • NAFLD in Psoriatic Disease: Identifying patients at high risk of serious liver disease. -Annals of the Rheumatic Diseases. May 2023.
  • Non-Alcoholic Fatty liver disease in spondyloarthritis: Identifying patients on therapy at high risk of serious liver disease. -British Journal of Rheumatology. April 2023.
  • Endovascular glue embolization for parastomal variceal bleeding: A retrospective analysis of patient outcomes.- Gut Abstracts for BASL 2022.
  • Outcomes following Immune Checkpoint inhibitor re-challenge in patients who developed grade 3 and 4 hepatotoxicity. -Poster presentation-EASL ILC 2022 (EASL, Abstract Number 3419).
  • UK Wide Evaluation of Second Line Therapies in Primary Biliary Cholangitis.- Poster presentation-EASL ILC 2021.
  • Multicentre evaluation of second-line therapies in primary biliary cholangitis: UK experience.- Conference Paper, GUT-BSG 2021.
  • Experience of shielding during the first wave of COVID-19 amongst UK patients with autoimmune hepatitis (AIH) -Conference Paper, GUT-BSG 2021.
  • T Cell response in immunosuppressed redo-liver transplant recipients after COVID 10 infection and after the first dose of vaccine against SARS COv-2.-Conference Paper, ILTS 2021.
  • Non-directed altruistic living liver donation: Evaluation and outcomes.- HPB-2020.
  • Ambulatory liver services avoid admissions and reduce length of stay with high patient satisfaction.-Conference paper, GUT-BSG 2018.
  • The risk of chronic kidney disease after liver transplantation is rising in parallel with the increased use of higher-risk grafts. -Journal of Hepatology, Vol 66, Issue 1, S192. & -Poster presentation by one of the authors at EASL ILC 2017.
  • Management of High-Risk Colonic Polyps -An Audit of Current Practice.- Poster presentation in GUT-BSG 2014.
  • Botulinum Toxin Use in Oesophageal Dysmotility.- Poster presentation GUT-BSG 2014.
  • Prospective Study of Peristomal Infections After Percutaneous Endoscopic Gastrostomy Over A 4-year Period.-Poster presentation UEG 2014.
  • Endoscopy Comfort- Views and Practices of BCSP (Bowel Cancer Screening Programme) Colonoscopists in Southwest England. 2012. - Poster presentation in SWG Meeting 2012.
  • Oral presentation on Long QT Interval – A Case Study in Southwest -Electrophysiology Group in 2007.

Certifications & Memberships

 Memberships

  • British Association for the Study of the Liver (BASL)
  • European Association for the Study of the Liver (EASL)
  • Royal College of Physicians, London (RCP London)

Frequently Asked Questions